Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02

[1]  T. Cloughesy,et al.  Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study , 2017, Journal of Neuro-Oncology.

[2]  Susan M. Chang,et al.  Response Assessment in Neuro-Oncology Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Prados,et al.  Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Uhm,et al.  Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial , 2013, Clinical Cancer Research.

[5]  Spain,et al.  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. , 2013, Neuro-oncology.

[6]  Susan M. Chang,et al.  Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. , 2012, Neuro-oncology.

[7]  Paul S Mischel,et al.  Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. , 2012, Cancer discovery.

[8]  M. Gilbert.  Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. , 2011, Seminars in Oncology.

[9]  H. Fine,et al.  A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. , 2011, Neuro-oncology.

[10]  Michael Platten,et al.  Pathway inhibition: emerging molecular targets for treating glioblastoma. , 2011, Neuro-oncology.

[11]  J. Wright,et al.  A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia , 2011, Leukemia.

[12]  W. Pao,et al.  High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer , 2010, Journal of Neuro-Oncology.

[13]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Susan M. Chang,et al.  Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Timothy F Cloughesy,et al.  Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.

[16]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[17]  Susan M. Chang,et al.  Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Prados,et al.  Phase II study of POLY-ICLC in recurrent anaplastic glioma-A North American Brain Tumor Consortium study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Susan M. Chang,et al.  Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[21]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Dirk Strumberg,et al.  The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines , 2005, Anti-cancer drugs.

[23]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[24]  E. Cohen-Jonathan,et al.  The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[26]  S. Wilhelm,et al.  BAY 43-9006: preclinical data. , 2002, Current pharmaceutical design.

[27]  E. Cohen-Jonathan,et al.  Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation , 2002, International journal of cancer.

[28]  A. Adjei,et al.  Novel targets for lung cancer therapy: part I. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Guha,et al.  Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. , 2001, Cancer research.

[30]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[31]  C. Bowden,et al.  Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A Guha,et al.  Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.

[33]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Guha.  Ras Activation in Astrocytomas and Neurofibromas , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[35]  T. Cloughesy,et al.  Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma , 2011, Cancer Chemotherapy and Pharmacology.

[36]  M. Prados,et al.  Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Adjei,et al.  Novel targets for lung cancer therapy: part II. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Bowden,et al.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.